Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darbepoetin alfa biosimilar - 3SBio

Next Previous
Drug Profile

Darbepoetin alfa biosimilar - 3SBio

Alternative Names: NuPIAO; Recombinant erythropoiesis stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - Shenyang Sunshine; SSS06

Latest Information Update: 24 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3SBio
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 11 Jul 2018 Phase-II clinical trials in Anaemia in China (IV) (3SBio pipeline, July 2018)
  • 11 Jul 2018 Phase-II for Anaemia in China (SC) (3SBio pipeline, July 2018)
  • 01 May 2018 The State Drug Administration, The People's Republic of China grants approval for phase II and phase III trials of Darbepoetin alfa biosimilar in Anaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top